Trial Purpose

This is a study to assess the pharmacokinetics, safety, and tolerability of pembrolizumab formulated with MK-5180 when administered as a SC injection to participants with advanced solid tumors. Participants will receive SC injections of MK-3475A containing one of 2 different concentrations (Conc) of pembrolizumab, Conc1 and Conc2, corresponding to a pembrolizumab dose level of dose 1 for Arms 1, 2, and 3 and dose 2 for Arm 4.

View full trial information on



When speaking to your doctor, please have the trial identifier number available.

About The Trial

Trial Phase Icon

Phase 1

Tests the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital.

Trial start Icon


  • Actual study start date September 21, 2021
  • Estimated primary completion date September 26, 2026
  • Estimated study completion date September 26, 2026


Conditions Icon


Advanced Or Metastatic Solid Tumors

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon



Trial locations